Core Viewpoint - The company, Enwei Pharmaceutical, anticipates a significant increase in net profit for the year 2025, projecting a rise of over 50% compared to the previous year [2][3]. Group 1: Performance Forecast - The performance forecast period is set from January 1, 2025, to December 31, 2025 [1]. - The expected net profit is projected to be positive and to increase by more than 50% [2]. Group 2: Communication with Auditors - The data related to the performance forecast is based on preliminary calculations by the company's finance department and has not yet been audited by the accounting firm [2]. - The company has had preliminary discussions with the accounting firm regarding the performance forecast, and there are no significant disagreements [2]. Group 3: Reasons for Performance Change - The primary reason for the anticipated increase in performance for 2025 is attributed to growth in main business revenue, which will lead to an increase in net profit, along with a reduction in the amortization costs of the equity incentive plan [3]. Group 4: Non-Recurring Gains - It is estimated that non-recurring gains and losses will impact net profit by approximately 7.5 million yuan [4]. Group 5: Additional Information - The performance forecast data is preliminary, and detailed financial data will be disclosed in the annual report for 2025 [5].
恩威医药股份有限公司 2025年度业绩预告